The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .
Dose‐Response Relationship of Ramipril in Patients with Mild‐to‐Moderate Hypertension
The dose-response relationship of ramipril was examined in 216 subjects with mild-to-moderate essential hypertension in a double-blind , placebo-controlled , multicenter study . Ramipril capsules ( 1.25 , 2.5 , 5 , or 10 mg ) or placebo capsules were administered once daily for 12 weeks . Significant reductions in supine and st and ing diastolic and systolic blood pressures were seen at end point in the ramipril 2.5 , 5 , and 10 mg treatment groups compared with placebo . The antihypertensive effect was greater at higher doses . The minimum effective dose of ramipril was 2.5 mg once daily
The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .